AVLAYAH
Mar 30, 2026
Denali’s AVLAYAH Win for Hunter Syndrome Marks Turning Point for Rare Disease Innovation
Summary AVLAYAH (tividenofusp alfa‑eknm) has received FDA accelerated approval as the first Hunter syndrome therapy specifically designed to treat neurologic manifestations by crossing the blood–brain barrier. The drug uses Denali’s TransportVehicle platform to fuse the IDS enzyme with a transferrin‑receptor...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
